{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T19:06:11Z","timestamp":1761419171750},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jacl.2017.08.014","type":"journal-article","created":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T21:00:18Z","timestamp":1504558818000},"page":"1485-1487","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin\/kexin type 9 inhibitor, alirocumab (Praluent)"],"prefix":"10.1016","volume":"11","author":[{"given":"Mohamed K.M.","family":"Shakir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh D.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinh Q.","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jacl.2017.08.014_bib1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacl.2017.08.014_bib2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity","volume":"23","author":"Sathasivam","year":"2012","journal-title":"Eur J Intern Med"},{"issue":"14","key":"10.1016\/j.jacl.2017.08.014_bib3","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/archinte.166.14.1519","article-title":"Presymptomatic neuromuscular disorders disclosed following statin treatment","volume":"166","author":"Tsivgoulis","year":"2006","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.jacl.2017.08.014_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"issue":"16","key":"10.1016\/j.jacl.2017.08.014_bib5","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.08.014_bib6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.jacl.2017.08.014_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.jacl.2017.08.014_bib8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/clinchem\/34.12.2460","article-title":"Activities of creatine kinase and its isoenzymes in serum in various skeletal muscle disorders","volume":"34","author":"Arenas","year":"1988","journal-title":"Clin Chem"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417304397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T02:53:12Z","timestamp":1602903192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417304397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1933287417304397"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.08.014","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of a patient with statin-induced myopathy and myotonic dystrophy type II with proprotein convertase subtilisin\/kexin type 9 inhibitor, alirocumab (Praluent)","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}